LIVIVO - Search results -

Search results

Result 1 - 10 of total 18

Search options

Article ; Online: Public Knowledge and Attitude towards Vitiligo: A Cross-Sectional Survey in Jordan.

Murshidi, Rand / Shewaikani, Nour / Al Refaei, Assem / Alfreijat, Balqis / Al-Sabri, Buthaina / Abdallat, Mahmoud / Murshidi, Muayyad / Khamis, Tala / Al-Dawoud, Yasmin / Alattar, Zahraa

International journal of environmental research and public health

2023 Volume 20, Issue 12

Abstract: Background: Vitiligo is an autoimmune disease affecting approximately 2% of the world's population. Besides vitiligo cosmetic issues, patients suffer from psychological comorbidities. This results from the stigmatization they encounter from surrounding ... ...

Abstract	Background: Vitiligo is an autoimmune disease affecting approximately 2% of the world's population. Besides vitiligo cosmetic issues, patients suffer from psychological comorbidities. This results from the stigmatization they encounter from surrounding individuals. Accordingly, the current study was the first to assess Jordanians' knowledge and attitude toward vitiligo. Methods: Data collection was completed by an online questionnaire consisting of four sections to capture participants' sociodemographic characteristics, previous exposure, and knowledge and attitude toward vitiligo. The analysis took place through R and RStudio. Results: Of our 994 surveyed participants, only 8.45% and 12.47% had a low level of vitiligo knowledge and negative total attitude score, respectively. Moreover, independent predictors of positive attitudes included younger age (18-30), high school education or lower, hearing about or living with a vitiligo patient, and higher knowledge scores. The highest prevalence of positive attitudes was observed when physicians were the source of knowledge. Conclusion: Some critical misconceptions were identified despite the Jordanian public having sufficient overall knowledge. Furthermore, higher knowledge reflected a higher prevalence of positive attitudes toward the patients. We recommend that future efforts target the public understanding of the nature of the disease and its being non-communicable. Moreover, we emphasize that medical knowledge should be communicated through qualified healthcare providers.
MeSH term(s)	Humans ; Cross-Sectional Studies ; Jordan ; Vitiligo/epidemiology ; Health Knowledge, Attitudes, Practice ; Surveys and Questionnaires
Language	English
Publishing date	2023-06-19
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2175195-X
ISSN	1660-4601 ; 1661-7827
ISSN (online)	1660-4601
ISSN	1661-7827
DOI	10.3390/ijerph20126183
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article: Coronavirus disease 2019 in solid organ transplant recipients in the setting of proactive screening and contact tracing of Qatar.

Alattar, Rand A / Shaar, Shahd H / Othman, Muftah / Abu Jarir, Sulieman H / Hashim, Samar M / Iqbal, Fatima / Rustom, Fatima / Almaslamani, Muna A / Omrani, Ali S

Qatar medical journal

2021 Volume 2021, Issue 2, Page(s) 23

Abstract: Background: Clinical data on Coronavirus Disease 2019 (COVID-19) in solid organ transplant (SOT) recipients are limited. We herein report the initial clinical experience with COVID-19 in SOT recipients in Qatar.: Methods: All SOT recipients with ... ...

Abstract	Background: Clinical data on Coronavirus Disease 2019 (COVID-19) in solid organ transplant (SOT) recipients are limited. We herein report the initial clinical experience with COVID-19 in SOT recipients in Qatar. Methods: All SOT recipients with laboratory-confirmed COVID-19 up to May 23, 2020 were included. Demographic and clinical data were extracted retrospectively from the hospital's electronic health records. Categorical data are presented as frequency and percentages, while continuous variables are summarized as medians and ranges. Results: Twenty-four SOT recipients with COVID-19 were identified (kidney 16, liver 6, heart 1, and liver and kidney 1). Organ transplantation preceded COVID-19 by a median of 60 months (range 1.7-184). The median age was 57 years (range 24-72), and 9 (37.5%) transplant recipients were females. Five (21%) asymptomatic patients were diagnosed through proactive screening. For the rest, fever (15/19) and cough (13/19) were the most frequent presenting symptoms. Five (20.8%) patients required invasive mechanical ventilation in the intensive care unit (ICU). Eleven (46%) patients developed acute kidney injury, including three in association with drug-drug interactions involving investigational COVID-19 therapies. Maintenance immunosuppressive therapy was modified in 18 (75%) patients, but systemic corticosteroids were not discontinued in any. After a median follow-up of 226 days (26-272), 20 (83.3%) patients had been discharged home, 2 (8.3%) were still hospitalized, 1 (4.2%) was still in the ICU, and 1 (4.2%) had died. Conclusions: Our results suggest that asymptomatic COVID-19 is possible in SOT recipients and that overall outcomes are not uniformly worse than those in the general population. The results require confirmation in large, international cohorts.
Language	English
Publishing date	2021-08-10
Publishing country	Qatar
Document type	Journal Article
ZDB-ID	3031075-1
ISSN	2227-0426 ; 0253-8253
ISSN (online)	2227-0426
ISSN	0253-8253
DOI	10.5339/qmj.2021.23
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study.

Alattar, Rand A / Abdalla, Shiema / Abdallah, Tasneem / Kazman, Rashid / Qadmour, Aseelah / Ibrahim, Tawheeda / Alhariri, Bassem / Shaar, Shahd H / Bajwa, Abeer / Alimam, Abeir / Qazi, Rabia / Ben Abid, Fatma / Daghfal, Joanne / Eldeeb, Ali / Shukri, Kinda / Elsayed, Ahmed / Rustom, Fatima / Alsamawi, Musaed / Abdelmajid, Alaaeldin /

Basulto, Miguel A P / Cobian, Armando A R / Abukhattab, Mohamed / Alkhal, Abdullatif / Almaslamani, Muna A / Omrani, Ali S

Journal of infection and public health

2022 Volume 15, Issue 10, Page(s) 1061–1064

Abstract: We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not ... ...

Abstract	We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. The unmatched cohort included 1493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001). Adverse events were common in both groups, but the 93.9% were Grades 1-3. Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.
MeSH term(s)	Humans ; COVID-19 ; SARS-CoV-2 ; Propensity Score ; Cohort Studies ; Retrospective Studies ; Antiviral Agents/adverse effects ; Treatment Outcome
Chemical Substances	favipiravir (EW5GL2X7E0) ; Antiviral Agents
Language	English
Publishing date	2022-08-27
Publishing country	England
Document type	Journal Article
ZDB-ID	2467587-8
ISSN	1876-035X ; 1876-0341
ISSN (online)	1876-035X
ISSN	1876-0341
DOI	10.1016/j.jiph.2022.08.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs.

A Elrayess, Mohamed / T Zedan, Hadeel / A Alattar, Rand / Abusriwil, Hatem / Al-Ruweidi, Mahmoud Khatib A A / Almuraikhy, Shamma / Parengal, Jabeed / Alhariri, Bassem / Yassine, Hadi M / A Hssain, Ali / Nair, Arun / Al Samawi, Musaed / Abdelmajid, Alaaeldin / Al Suwaidi, Jassim / Omar Saad, Mohamed / Al-Maslamani, Muna / Omrani, Ali S / Yalcin, Huseyin C

Blood pressure

2022 Volume 31, Issue 1, Page(s) 80–90

Abstract: Purpose: This study examines the effect of antihypertensive drugs on ACE2 and Angiotensin II levels in hypertensive COVID-19 patients.: Introduction: Hypertension is a common comorbidity among severe COVID-19 patients. ACE2 expression can be ... ...

Abstract	Purpose: This study examines the effect of antihypertensive drugs on ACE2 and Angiotensin II levels in hypertensive COVID-19 patients. Introduction: Hypertension is a common comorbidity among severe COVID-19 patients. ACE2 expression can be modulated by antihypertensive drugs such as ACEis and ARBs, which may affect COVID-19's prognosis. BB and CCB reduce mortality, according to some evidence. Their effect on circulating levels of ACE2 and angiotensin II, as well as the severity of COVID-19, is less well studied. Materials and methods: The clinical data were collected from 200 patients in four different antihypertensive medication classes (ACEi, ARB, BB, and CCB). Angiotensin II and ACE2 levels were determined using standard ELISA kits. ACE2, angiotensin II, and other clinical indices were evaluated by linear regression models. Results: Patients on ACEi ( Conclusion: We found different levels of soluble ACE2, and angiotensin II are observed among COVID-19 patients taking different antihypertensive medications and exhibiting varying levels of disease severity. COVID-19 severity increases with elevated ACE2 levels and lower angiotensin II levels indicating that BB treatment reduces severity regardless of levels of ACE2 and angiotensin II.
MeSH term(s)	Angiotensin II ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme 2 ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antihypertensive Agents/therapeutic use ; COVID-19/drug therapy ; Humans ; Hypertension/complications ; Hypertension/drug therapy
Chemical Substances	Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Angiotensin II (11128-99-7) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
Language	English
Publishing date	2022-04-25
Publishing country	England
Document type	Journal Article
ZDB-ID	1170048-8
ISSN	1651-1999 ; 1651-2480 ; 0803-7051 ; 0803-8023
ISSN (online)	1651-1999 ; 1651-2480
ISSN	0803-7051 ; 0803-8023
DOI	10.1080/08037051.2022.2055530
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3843: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Tocilizumab for the treatment of severe coronavirus disease 2019.

Alattar, Rand / Ibrahim, Tawheeda B H / Shaar, Shahd H / Abdalla, Shiema / Shukri, Kinda / Daghfal, Joanne N / Khatib, Mohamed Y / Aboukamar, Mohamed / Abukhattab, Mohamed / Alsoub, Hussam A / Almaslamani, Muna A / Omrani, Ali S

Journal of medical virology

2020 Volume 92, Issue 10, Page(s) 2042–2049

Abstract: Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed ... ...

Abstract	Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. Twenty-five patients were included, median age was 58 years (interquartile range, 50-63) and the majority were males (92%). Co-morbidities included diabetes mellitus (48%), chronic kidney disease (16%), and cardiovascular disease (12%). Fever (92%), cough (84%), and dyspnea (72%) were the commonest presenting symptoms. All patients received at least two concomitant investigational antiviral agents. Median oral temperature was on day 1, 3, and 7 was 38.0°C, 37.3°C (P = .043), and 37.0°C (P = .064), respectively. Corresponding median C-reactive protein was 193 and 7.9 mg/L (P < .0001) and <6 mg/L (P = .0001). Radiological improvement was noted in 44% of patients by day 7% and 68% by day 14. Nine patients (36%) were discharged alive from intensive care unit and three (12%) died. The proportion of patients on invasive ventilation declined from (84%) at the time of tocilizumab initiation to 60% on day 7 (P = .031) and 28% on day 14 (P = .001). The majority (92%) of patients experienced at least one adverse event. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilatory support requirements. Given the study's limitations, the results require assessment in adequately powered randomized controlled trials.
MeSH term(s)	Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; C-Reactive Protein/analysis ; COVID-19/drug therapy ; Female ; Humans ; Male ; Middle Aged ; Qatar ; Respiration, Artificial ; Retrospective Studies
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antiviral Agents ; C-Reactive Protein (9007-41-4) ; tocilizumab (I031V2H011)
Keywords	covid19
Language	English
Publishing date	2020-05-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.25964
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study

Rand A. Alattar / Shiema Abdalla / Tasneem Abdallah / Rashid Kazman / Aseelah Qadmour / Tawheeda Ibrahim / Bassem Alhariri / Shahd H. Shaar / Abeer Bajwa / Abeir Alimam / Rabia Qazi / Fatma Ben Abid / Joanne Daghfal / Ali Eldeeb / Kinda Shukri / Ahmed Elsayed / Fatima Rustom / Musaed Alsamawi / Alaaeldin Abdelmajid /

Miguel A.P. Basulto / Armando A.R. Cobian / Mohamed Abukhattab / Abdullatif Alkhal / Muna A. Almaslamani / Ali S. Omrani

Journal of Infection and Public Health, Vol 15, Iss 10, Pp 1061-

2022 Volume 1064

Abstract	We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. The unmatched cohort included 1493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001). Adverse events were common in both groups, but the 93.9% were Grades 1–3. Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.
Keywords	COVID-19 ; SARS-CoV-2 ; Pneumonia ; Favipiravir ; Antiviral therapy ; Infectious and parasitic diseases ; RC109-216 ; Public aspects of medicine ; RA1-1270
Subject code	610
Language	English
Publishing date	2022-10-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Tocilizumab for the treatment of severe coronavirus disease 2019

J. med. virol

Abstract	Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. Twenty-five patients were included, median age was 58 years (interquartile range, 50-63) and the majority were males (92%). Co-morbidities included diabetes mellitus (48%), chronic kidney disease (16%), and cardiovascular disease (12%). Fever (92%), cough (84%), and dyspnea (72%) were the commonest presenting symptoms. All patients received at least two concomitant investigational antiviral agents. Median oral temperature was on day 1, 3, and 7 was 38.0°C, 37.3°C (P = .043), and 37.0°C (P = .064), respectively. Corresponding median C-reactive protein was 193 and 7.9 mg/L (P < .0001) and <6 mg/L (P = .0001). Radiological improvement was noted in 44% of patients by day 7% and 68% by day 14. Nine patients (36%) were discharged alive from intensive care unit and three (12%) died. The proportion of patients on invasive ventilation declined from (84%) at the time of tocilizumab initiation to 60% on day 7 (P = .031) and 28% on day 14 (P = .001). The majority (92%) of patients experienced at least one adverse event. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilatory support requirements. Given the study's limitations, the results require assessment in adequately powered randomized controlled trials.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #175880
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.

Journal of medical virology

2020 Volume 93, Issue 3, Page(s) 1678–1686

Abstract: Background: The role of convalescent plasma therapy for patients with coronavirus disease 2019 (COVID-19) is unclear.: Methods: We retrospectively compared outcomes in a cohort of critical COVID-19 patients who received standard care (SC Group) and ... ...

Abstract	Background: The role of convalescent plasma therapy for patients with coronavirus disease 2019 (COVID-19) is unclear. Methods: We retrospectively compared outcomes in a cohort of critical COVID-19 patients who received standard care (SC Group) and those who, in addition, received convalescent plasma (CP Group). Results: In total, 40 patients were included in each group. The median patient age was 53.5 years (interquartile range [IQR] 42-60.5), and the majority of patients required invasive ventilation (69, 86.2%). Plasma was harvested from donors after a median of 37 days (IQR 31-46) from the first positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) result and 26 days (IQR 21-32) after documented viral clearance; it was administered after a median of 10 days (IQR 9-10) from the onset of symptoms and 2.5 days (IQR 2-4) from admission to intensive care unit. The primary endpoint of improvement in respiratory support status within 28 days was achieved in 26 patients (65%) in the SC Group and 31 patients (77.5%) in the CP Group (p = .32). The 28-day all-cause mortality (12.5% vs. 2.5%; p = .22) and viral clearance (65% vs. 55%; p = .49) were not significantly different between the two groups. Convalescent plasma was not significantly associated with the primary endpoint (adjusted hazard ratio 0.87; 95% confidence interval 0.51-1.49; p = .62). Adverse events were balanced between the two study groups. Conclusion: In severe COVID-19, convalescent plasma therapy was not associated with clinical benefits. Randomized trials are required to confirm our findings.
MeSH term(s)	Adult ; COVID-19/immunology ; COVID-19/therapy ; Female ; Humans ; Immunization, Passive/methods ; Male ; Middle Aged ; Plasma/immunology ; Retrospective Studies ; SARS-CoV-2/immunology ; Severity of Illness Index ; Treatment Outcome
Keywords	covid19
Language	English
Publishing date	2020-10-05
Publishing country	United States
Document type	Journal Article
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.26537
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: RON, ROR1 and SUSD2 expression in tissues of endometrial carcinoma patients. Clinicopathological and prognostic implications.

Abdelbary, Abeer M / Kaf, Randa Mohamed / Lashin, Mohamed Elbakry / Alattar, Ahmed Z / Elsayed, Dalia Hamouda / Amin, Ahmed F / Gertallah, Loay M / Yehia, Ahmed Mohamed

Contemporary oncology (Poznan, Poland)

2022 Volume 26, Issue 2, Page(s) 109–122

Abstract: Introduction: Endometrial carcinoma is now considered a common female gynecologic cancer with increasing incidence, with 13-25% of patients being still liable to recurrence and metastasis, which needs further studies to detect novel targets and new ... ...

Abstract	Introduction: Endometrial carcinoma is now considered a common female gynecologic cancer with increasing incidence, with 13-25% of patients being still liable to recurrence and metastasis, which needs further studies to detect novel targets and new therapies. The aim of the study was evaluate tissue expression of RON, ROR1 and SUSD2 in endometrial carcinoma and atypical endometrial hyperplasia using immunohistochemistry and correlate their expression with clinical, pathological and prognostic parameters of patients. Material and methods: We included samples from 100 patients with endometrial carcinoma. Sections from paraffin blocks were stained with RON, ROR1 and SUSD2 using immunohistochemistry. Correlations between marker expression, clinicopathological features and prognostic samples were evaluated. Results: Upregulation of RON and ROR1 and downregulation of SUSD2 expression were found in endometrial carcinoma more than atypical endometrial hyperplasia ( Conclusions: Upregulation of RON and ROR1 and downregulation of SUSD2 lead to promotion of endometrial cancer cell proliferation, migration, epithelial-mesenchymal transition, and invasion.
Language	English
Publishing date	2022-06-30
Publishing country	Poland
Document type	Journal Article
ISSN	1428-2526
ISSN	1428-2526
DOI	10.5114/wo.2022.118245
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study

ALATTAR, Rand A / ABDALLA, Shiema / ABDALLAH, Tasneem AK / KAZMAN, Rashid / QADMOUR, Aseelah / IBRAHIM, Tawheeda BH / ALHARIRI, Bassem / SHAAR, Shahd / BAJWA, Abeer / ALIMAM, Abeir BH / QAZI, Rabia / BEN ABID, Fatma / DAGHFAL, Joanne / ELDEEB, Ali M / SHUKRI, Kinda / ELSAYED, Ahmed / RUSTOM, Fatima / ALSAMAWI, Musaed / ABDELMAJID, Alaaeldin /

BASULTO, Miguel AP / COBIAN, Armando AR / ABUKHATTAB, Mohamed / ALMASLAMANI, Muna A / ALKHAL, Abdullatif / OMRANI, Ali S

medRxiv

Abstract: Background We investigated clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Methods Patients who between 23 May 2020 and 18 July 2020 received 24 hours or more of favipiravir were assigned to the favipiravir group, while those who ... ...

Abstract	Background We investigated clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Methods Patients who between 23 May 2020 and 18 July 2020 received 24 hours or more of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. Cox regression was used to examine associations with the primary endpoint. Results The unmatched cohort included 1,493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Favipiravir was started within a median of 5 days from symptoms onset. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P <0.001). In the adjusted Cox proportional hazards model, favipiravir therapy was not associated 28-day clinical improvement (adjusted hazard ratio 0.978, 95% confidence interval 0.862 to 1.109, P 0.726). Adverse events were common in both groups, but the 93.9% were Grades 1 to 3. Conclusion Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.
Keywords	covid19
Language	English
Publishing date	2021-11-30
Publisher	Cold Spring Harbor Laboratory Press
Document type	Article ; Online
DOI	10.1101/2021.11.29.21267042
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

Kategorien

Inter-library loan at ZB MED